Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9937339 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2SLC29A1HDAC1PIK3R1PIK3CA | |
| SCHEMBL30670395 | 0.79 | SLC29A1 (0.40) | SMN1; SMN2SLC29A1HDAC1PIK3R1PIK3CA | |
| SCHEMBL10008467 | 0.78 | SMN1; SMN2 (0.38) | SMN1; SMN2HDAC1PIK3R1PIK3CALMNA | |
| SCHEMBL9936755 | 0.77 | SMN1; SMN2 (0.37) | SMN1; SMN2SLC29A1HDAC1PIK3R1PIK3CA | |
| SCHEMBL3325399 | 0.76 | SMN1; SMN2 (0.41) | SMN1; SMN2SLC29A1HDAC1PIK3R1PIK3CA | |
| SCHEMBL18050658 | 0.74 | — | — | |
| SCHEMBL1113965 | 0.74 | SMN1; SMN2 (0.38) | SMN1; SMN2SLC29A1HDAC1PIK3R1PIK3CA | |
| SCHEMBL30670406 | 0.74 | SMN1; SMN2 (0.38) | SMN1; SMN2SLC29A1HDAC1PIK3R1PIK3CA | |
| SCHEMBL25229494 | 0.74 | SMN1; SMN2 (0.42) | SMN1; SMN2SLC29A1HDAC1NPSR1MAPT | |
| SCHEMBL31339118 | 0.74 | PIM1 (0.40) | SMN1; SMN2SLC29A1HDAC1PIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2022-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MTOR | SMN1; SMN2 3443/4885SLC29A1 1169/4885HDAC1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.